The Association of Community Cancer Centers, in collaboration with AstraZeneca, Merck, and partner organizations: the Association for Molecular Pathology, the National Society of Genetic Counselors, and the Society of Gynecologic Oncology, has launched the Barriers to Quality Care in Ovarian Cancer project.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
